Notably, mutations in the BRAF gene, which is a potent modulator of the MAPK pathway, are observed in approximately 8–12% of CRC patients, with BRAF-V600E accounting for over 95% of these mutations [9,10]. The gene discussed is BRAF; the disease is colorectal carcinoma.